Biomedical markers of response to intravesical BCG treatment in high-grade non-muscle invasive (PTA and PT1) transitional cell carcinoma of the bladder
Intravesical Bacillus Calmette–Guérin (BCG) immunotherapy is the main treatment for bladder high-grade non-muscle invasive transitional cell carcinoma (HGNMITCC) following initial resection. Unfortunately, about 30% of patients will not respond to treatment and they carry a high risk of disease prog...
| Main Author: | |
|---|---|
| Published: |
University of Brighton
2015
|
| Subjects: | |
| Online Access: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.678922 |
| Summary: | Intravesical Bacillus Calmette–Guérin (BCG) immunotherapy is the main treatment for bladder high-grade non-muscle invasive transitional cell carcinoma (HGNMITCC) following initial resection. Unfortunately, about 30% of patients will not respond to treatment and they carry a high risk of disease progression. The alternative, radical cystectomy, has major risks with high morbidity and mortality. The ability to predict the response to BCG treatment would be a useful tool in the selection of appropriate treatment modalities. This study investigated a variety of detectable immune responses in blood and urine to establish if there were differences between responders and non-responders to BCG treatment. We evaluated whether there were detectable immunological differences in blood or urine that could explain or predict outcome. |
|---|